Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Perhaps there’s reference to something other than ELTP shares.
Perhaps there’s reference to something other than ELTP shares.
I eagerly await those milestone updates along with other shareholders. Let’s have some news to move the needle closer to NASDAQ.
Selling now would only be ridiculous. Probably the most ridiculous recommendation I have seen on this board. No buyer would even exist until Elite can survive post Lannett. As of now most of their revenue is at risk. Nasrat is forecasting this year to be equivalent to prior, but the first couple quarters might be a little ugly. 10Q in Aug will be the first quarter released flying solo. If top line is really bad, Nasrat should focus on current quarter trend, assuming it’s more positive. Looking forward to seeing margins in a couple of quarters.
So technically 62 reported for this 10K due this month
Actually he’s 61, much younger per 10K
It means he combines the two for a sale to another party.
That’s simply an example of what could take place with the largest shareholder having significant sway in any shareholder proposal while being President, CEO& Chairman. He needs to cash out sometime soon as he is ~68 years old. His desired selling price may be far lower than what other shareholders may desire, but there’s nothing that can be done due to all the free shares given him over the years, including for the crap drugs that came along with him as CEO layered on by the significant dilution for SequestOx that went nowhere, but hey, “no one can stop us”.
More shares = more % ownership marching towards being the sole voter that counts for any proposals such as a Mikah merger.
This is their fiscal year end 10K. They have until end of June to file. Fiscal year ended 3/31 and have 90 days to submit. They do have new CFO, but would expect them to still file timely.
To my knowledge this only applies to SPACs that trade less than $5.
In the past management has discussed various topics such as reverse splits, getting to NASDAQ, various strategies, etc. Company has fallen short on many of these, but doesn’t stop them from discussing potential plans with shareholders. All protected by Safe Harbor.
No one puts out a PR about possible PR. That would be really ridiculous. They can discuss potential strategies to increase shareholder value during cc’s, but will be protected forward looking language.
Not sure about the nudes, but she is limited by the CEO. It’s not IR you should be directing frustration at.
“Rather quickly” note from 2012.
Upside is margins will improve when CEO cashes out of his 50% Adderall ownership, but that depends on Elite surviving post-Lannett.
I’d say the rapid growth in shares outstanding over CEO’s tenure is something to write home amount.
Completely agree. There is no decent, consistent volume to make any profit. Mathematically it makes no sense to short ELTP, but often retail shareholders believe in conspiracy theories as the world is always out to get them and basic facts get ignored.
Zero impact for Elite. Just wishful thinking is all it is by retail shareholders.
Interesting, thanks for the recent and older commentary.
Isn’t our antimetabolite a small $42M market generic? Xeloda is much larger and Cytoxan I thought was an injectable, which Elite doesn’t do.
I could be wrong, but I don’t think Elite’s antimetabolite filing is either of these.
What do you mean? We’ll likely hear early next year on FDA’s response to the submission for approval.
Why does the independent BOD pay you so much for so little shareholder return achieved over the last 10 years? :)
A good read except that the article is highly misleading. The author states that Elite may potentially bring in tens of millions from the antimetabolite ANDA. That is the total market for all competitors. If no other competitors existed sure that I’d what Elite would be after, but not the case. Highly misleading that leads to unfortunate misinterpretation from inexperienced investors.
Like Elite? Come on.
Purdue has been able to file new patents for OxyContin 13 times with the US Patent and Trademark Office over the past decade, thereby extending its exclusive selling rights on the drug through 2030.
They don’t want competitors to know they have nothing going on. Lol
Except no one will buy it. Can’t be price competitive. which is why CEO says it’s not being pursued multiple times. Give it up.
You agree simply showing the level of inconsistency and incompetence of leadership.
Beg to differ and so would the SEC. Wonder why Elite reports study results? Because it is a material event to be reported.
Of course, he decided to postpone a material event. Lol
Why would this not happen on NASDAQ? If company does nothing to get word out about prospects, future plans, forecasts, growth, strategy, etc it doesn’t matter if they are on the OTC or NASDAQ. There would be a little buying overtime for index/mutual funds, but wouldn’t be a significant amount. No good story (or trust to get there) = stagnant share price
The only monster in the room is the monstrous amount of outstanding shares.
100% agree that this isn’t the right timing. I’m not pushing for that. Nasrat’s strategy is to devote all excess cash to R&D and build out sales infrastructure. He’s not going to do a buyback, as much as I’d like him to. Knowing this. ES is only way to clean up the capital structure mess.
They’ll have to RS to get to NASDAQ. They can’t organically get there.
I believe he passed away.
There is no June 31st. :)
They do have to wait until audit is complete, for which smaller companies can be deprioritized depending on portfolio of auditor.
Hopefully you can find out well before June 31st comes around. Might be waiting a while. :)
And how do you calculate public float without share price? That’s 50% of the calculation.
They used to fall under the accelerated filer status several years back when share price was much higher.